Bone and collagen markers in paediatric practice

International Journal of Clinical Practice

Volumn 52, Issue 8, 1998, Pages 557-565

  Crofton, P M ^a   Kelnar, C J H ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; COLLAGEN;

BODY HEIGHT; BONE; BONE DENSITY; BONE GROWTH; BONE MINERAL; BONE TURNOVER; CHILD; DIAGNOSTIC VALUE; FRACTURE; HUMAN; OSTEOPOROSIS; PEDIATRICS; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK;

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; AMINO ACIDS; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CHILD; CHILD NUTRITION DISORDERS; CHILD, PRESCHOOL; FEMALE; GROWTH DISORDERS; HUMANS; ISOENZYMES; MALE; PEPTIDE FRAGMENTS; PROCOLLAGEN;

EID: 0031743984     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Uebelhart D, Schlemmer A, Johansen J et al. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J Clin Endocrinol Metab 1991; 72: 367-373.
2. Hansen MA, Overgaard K, Riis BJ et al. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991; 303: 961-964.
3. Akesson K, Ljunghall S, Jonsson B et al. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women. J Bone Miner Res 1995; 10: 1823-1829.
4. Garnero P, Hausherr E, Chapuy MC et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11: 1531-1538.
5. Harris ET, Gertz BJ, Genant HK et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993; 76: 1399-1403.
6. Shaw NJ, Bishop NJ. Mineral accretion in growing bones - a framework for the future? Arch Dis Child 1995; 72: 177-179.
7. Wales JKH, Milner RDG. Knemometry in assessment of linear growth. Arch Dis Child 1987; 62: 166-171.
8. Risteli L, Risteli J. Biochemical markers of bone metabolism. Ann Med 1993; 25: 385-393.
9. Stein GS, Lian JB, Owen TA. Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J 1990; 4: 111-123.
10. Ohlsson C, Isgaard J, Törnell J et al. Endocrine regulation of longitudinal bone growth. Acta Paed Scand 1993; 82(suppl 391): 33-40.
11. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 1996; 17: 333-368.
12. Crofton PM. Wheat-germ lectin affinity electrophoresis for alkaline phosphatase isoforms in children: age-dependent reference ranges and changes in liver and bone disease. Clin Chem 1992; 38: 663-670.
13. Durham BH, Robinson J, Fraser WD. Differences in the stability of intact osteocalcin in serum, lithium heparin plasma and EDTA plasma. Ann Clin Biochem 1995; 32: 422-423.
14. Friedman A, Heiliczer J, Gundberg C et al. Serum osteocalcin concentrations in children with chronic renal insufficiency who are not undergoing dialysis. J Pediatr 1990; 116(suppl): S55-S59.
15. Delmas PD, Malaval L, Arlot ME et al. Serum bone gla-protein compared to bone histomorphometry in endocrine diseases. Bone 1985; 6: 339-341.
16. Eastell R, Delmas PD, Hodgson SF et al. Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J Clin Endocrinol Metab 1988; 67: 741-748.
17. Brixen K, Nielsen HK, Eriksen EF et al. Efficacy of wheat germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralization rate: comparison to serum total alkaline phosphatase and serum bone gla-protein. Calcif Tissue Int 1989; 44: 93-98.
18. Erikson EF, Charles P, Melsen F et al. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 1993; 8: 127-132.
19. Charles P, Mosekilde L, Risteli L et al. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner 1994; 24: 81-94.
20. Delmas PD, Schlemmer A, Gineyts E et al. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Min Res 1991; 6: 639-644.
21. Eastell R, Hampton L, Colwell A et al. Urinary collagen crosslinks are highly correlated with radioisotopic measurements of bone resorption. In: Christiansen C, Overgaard K, Eds. Osteoporosis. Copenhagen: Osteopress ApS, 1990; 469-470.
22. Clark LC, Beck E. Plasma 'alkaline' phosphatase activity. I. Normative data for growing children. J Pediatr 1950; 36: 335-341.
23. Jasin HE, Fink CW, Wise W et al. Relationship between urinary hydroxyproline and growth. J Clin Invest 1962; 41: 1928-1935.
24. Round JM. Plasma calcium, magnesium, phosphorus, and alkaline phosphatase levels in normal British schoolchildren. BMJ 1973; 3: 137-140.
25. Fleisher GA, Eickelberg ES, Elveback LR. Alkaline phosphatase activity of children and adolescents. Clin Chem 1977; 23: 469-472.
26. Krabbe S, Christiansen C, Rodbro P et al. Pubertal growth as reflected by simultaneous changes in bone mineral content and serum alkaline phosphatase. Acta Paediatr Scand 1980; 69: 49-52.
27. Schiele F, Henny J, Hitz J et al. Total bone and liver alkaline phosphatases in plasma: biological variations and reference limits. Clin Chem 1983; 29: 634-641.
28. Widhalm K, Hölzl M. Changes of alkaline phosphatase, inorganic phosphorus and total calcium in sera of 11 to 17 year old healthy adolescents, and their relationship to growth. J Clin Chem Clin Biochem 1985; 23: 711-717.
29. Cole DEC, Carpenter TO, Gundberg CM. Serum osteocalcin concentrations in children with metabolic bone disease. J Pediatr 1985; 106: 770-776.
30. Trivedi P, Hindmarsh P, Risteli J et al. Growth velocity, growth hormone therapy, and serum concentrations of the amino-terminal propeptide of type III procollagen. J Pediatr 1989; 114: 225-230.
31. Danne T, Grüters A, Schuppan D et al. Relationship of procollagen type III propeptide-related antigens in serum to somatic growth in healthy children and patients with growth disorders. J Pediatr 1989; 114: 257-260.
32. Saggese G, Bertelloni S, Baroncelli GI et al. Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1st year of life to adulthood and in metabolic bone diseases. Eur J Pediatr 1992; 151: 764-768.
33. Hertel NT, Stoltenberg M, Juul A et al. Serum concentrations of type I and III procollagen propeptides in healthy children and girls with central precocious puberty during treatment with gonadotrophin-releasing hormone analog and cyproterone acetate. J Clin Endocrinol Melab 1993; 76: 924-927.
34. Rauch F, Schönau E, Woitge H et al. Urinary excretion of hydroxy-pyridinium cross-links of collagen reflects skeletal growth velocity in normal children. Exp Clin Endocrinol 1994; 102: 94-97.
35. Bollen AM, Eyre DR. Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides. Bone 1994; 15: 31-34.
36. Rauch F, Schnabel D, Seibel MJ et al. Urinary excretion of galactosylhydroxylysine is a marker of growth in children. J Clin Endocrinol Metab 1995; 80: 1295-1300.
37. Fujimoto S, Kubo T, Tanaka H et al. Urinary pyridinoline and deoxypyridinoline in healthy children and in children with growth hormone deficiency. J Clin Endocrinol Metab 1995; 80: 1922-1928.
38. Bouillon R, Bex M, van Herck E et al. Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellilus. J Clin Endocrinol Metab 1995; 80: 1194-1202.
39. Rauch F, Rauch R, Woitge HW et al. Urinary immunoreactive deoxypyridinoline in children and adolescents: variations with age, sex and growth velocity. Scand J Clin Lab Invest 1996; 56: 715-719.
40. Rauch F, Stabrey A, Seibel MJ et al. Pediatric reference values for the urinary excretion of a collagen type I-specific, octapeptide-related epitope, a new marker of bone resorption. Clin Lab 1996; 42: 363-367.
41. Marowska J, Kobylinska, Lukaszkiewicz J et al. Pyridinium crosslinks of collagen as a marker of bone resorption rates in children and adolescents: normal values and clinical application. Bone 1996; 19: 669-677.
42. Crofton PM, Wade JC, Taylor MRH et al. Serum concentrations of the carboxyterminal propeptide of type I procollagen, the aminoterminal propeptide of type III procollagen, the cross-linked carboxyterminal telopeptide of type I collagen and their interrelationships in schoolchildren. Clin Chem 1997; 43: 1577-1581.
43. Tobiume H, Kanzaki S, Hida S et al. Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy. J Clin Endocrinol Metab 1997; 82: 2056-2061.
44. Round JM, Butcher S, Steele R. Changes in plasma inorganic phosphorus and alkaline phosphatase activity during the adolescent growth spurt. Ann Hum Biol 1979; 6: 129-136.
45. Round JM. Changes in plasma urate, creatinine, alkaline phosphatase and the 24 hour excretion of hydroxyproline during sexual maturation in adolescents. Ann Hum Biol 1980; 7: 83-88.
46. Blumsohn A, Hannon RA, Wrate R et al. Biochemical markers of bone turnover in girls during puberty. Clin Endocrinol 1994; 40: 663-670.
47. De Ridder CM, Netelenbos C, Roos JC et al. Bone growth and biochemical markers in Dutch pubertal girls. Horm Res 1996; 46(suppl 2): 80.
48. Sorva R, Anttila R, Siimes MA et al. Serum markers of collagen metabolism and serum osteocalcin in relation to pubertal development in 57 boys at 14 years of age. Pediatr Res 1997; 42: 528-532.
49. Trivedi P, Risteli J, Risteli L et al. Serum concentrations of the type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children with growth disorders. Pediatr Res 1991; 30: 276-280.
50. Allen DB, Goldberg BD. Stimulation of collagen synthesis and linear growth by growth hormone in glucocorticoid-treated children. Pediatrics 1992; 89: 416-421.
51. Kubo T, Tanaka H, Inoue M et al. Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children with growth hormone (GH) deficiency during GH therapy. Bone 1995; 17: 397-401.
52. Kanzaki S, Hosoda K, Moriwake T et al. Serum propeptide and intact molecular osteocalcin in normal children and children with growth hormone (GH) deficiency: a potential marker of bone growth and response to GH therapy. J Clin Endocrinol Metab 1992; 75: 1104-1109.
53. Crofton PM, Stirling HF, Schönau E et al. Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children. Clin Endocrinol 1996; 44: 385-394.
54. Saggese G, Baroncelli GI, Bertelloni S et al. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr 1993; 122: 37-45.
55. Sartorio A, Conti A, Monzani M. New markers of bone and collagen turnover in children and adults with growth hormone deficiency. Postgrad Med J 1993; 69: 846-850.
56. Tapanainen P, Risteli L, Knip M et al. Serum aminoterminal propeptide of type III procollagen: a potential predictor of the response to growth hormone therapy. J Clin Endocrinol Metab 1988; 67: 1244-1249.
57. Wales JKH, Gibson AT. Short term growth: rhythms, chaos, or noise? Arch Dis Child 1994; 71: 84-89.
58. Crofton PM, Stirling HF, Kelnar CJH. Bone alkaline phosphatase and height velocity in short normal children undergoing growth-promoting treatments: a longitudinal study. Clin Chem 1995; 41: 672-678.
59. Saggese G, Baroncelli GI, Bertelloni S et al. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children. Pediatr Res 1994; 35: 409-415.
60. Shaw NJ. Dutton J, Fraser WD et al. Urinary pyridinoline and deoxypyridinoline excretion in children. Clin Endocrinol 1995; 42: 607-612.
61. Kruse K, Kracht U. Evaluation of serum osteocalcin as an index of altered bone metabolism. Eur J Pediatr 1986; 145: 27-33.
62. Greig F, Casas J, Castells S. Changes in plasma osteocalcin concentrations during treatment of rickets. J Pediatr 1989; 114: 820-823.
63. Macfarlane JD, Frölich M, Papapoulos SE. Serum osteocalcin levels before and after 1,25 dihydroxy-vitamin D stimulation in a family with hypophosphatasia. Bone 1991; 12: 261-263.
64. Kruse K, Reiss I, Inderrieden D et al. Biochemical markers of bone turnover in diseases of extracellular calcium and phosphate metabolism. In: Schönau E, Ed. Paediatric osteology: new developments in diagnostics and therapy. Amsterdam: Elsevier, 1996; 203-220.
65. Byers PH. Disorders of collagen biosynthesis and structure. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Eds. The metabolic and molecular bases of inherited disease, 7th edn. New York: McGraw-Hill, 1995; 4029-4077.
66. Brenner RE, Schiller B, Vetter U et al. Serum concentrations of procollagen I C-terminal propeptide, osteocalcin and insulin-like growth factor-I in patients with non-lethal osteogenesis imperfecta. Acta Paediatr 1993; 82: 764-767.
67. Minisola S, Piccioni AL, Rosso R et al. Reduced serum levels of carboxy-terminal propeptide of human type I procollagen in a family with type I-A osteogenesis imperfecta. Metabolism 1994; 43: 1261-1265.
68. Antoniazzi F, Bertoldo F, Mottes M et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen. J Pediatr 1996; 129: 432-439.
69. Proszynska K, Wieczorek E, Olszaniecka M et al. Collagen peptides in osteogenesis imperfecta, idiopathic juvenile osteoporosis and Ehlers-Danlos syndrome. Acta Paediatr 1996; 85: 688-691.
70. Baroncelli GI, de Luca F, Magazzú G et al. Bone demineralization in cystic fibrosis: evidence of imbalance between bone formation and degradation. Pediatr Res 1997; 41: 397-403.
71. Bernstein BH, Stobie D, Singsen BH et al. Growth retardation in juvenile rheumatoid arthritis (JRA). Arthritis Rheum 1977; 20: 212-216.
72. Elsasser U, Wilkins B, Hesp R et al. Bone rarefaction and crush fractures in juvenile chronic arthritis. Arch Dis Child 1982; 57: 377-380.
73. Bianchi ML, Bardare M, Caraceni MP et al. Bone metabolism in juvenile rheumatoid arthritis. Bone Miner 1990; 9: 153-162.
74. Hopp R, Degan J, Gallagher JC et al. Estimation of bone mineral density in children with juvenile rheumatoid arthritis. J Rheumatol 1991; 18: 1235-1239.
75. Reed A, Haugen M, Pachman LM et al. Abnormalities in serum osteocalcin values in children with chronic rheumatic diseases. J Pediatr 1990; 116: 574-580.
76. Hillman L, Cassidy JT, Johnson L et al. Vitamin D metabolism and bone mineralization in children with juvenile rheumatoid arthritis. J Pediatr 1994; 124: 910-916.
77. Reed AM, Haugen M, Pachman LM et al. Repair of osteopenia in children with juvenile rheumatoid arthritis. J Pediatr 1993; 122: 693-696.
78. Klein GL, Herndon DN, Langman CB et al. Long-term reduction in bone mass after severe burn injury in children. J Pediatr 1995; 126: 252-256.
79. Olszaniecka M, Lebiedowski M, Lorenc RS et al. Dynamics of the course of idiopathic juvenile osteoporosis. Polski Tygodnik Lekarski 1993; 48(suppl 3): 20-23.
80. Lieuw-a-Fa M, Sierra RI, Specker BL. Carboxy-terminal propeptide of human type I collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age. J Bone Miner Res 1995; 10: 849-853.
81. Crofton PM, Stirling HF, Schönau E et al. Collagen markers and bone alkaline phosphatase as predictors of bone turnover and growth. In: Schönau E, Ed. Paediatric osteology: new developments in diagnostics and therapy. Amsterdam: Elsevier, 1996; 241-250.
82. Carey DE, Rowe JC, Goetz CA. Growth and phosphorus metabolism in premature infants fed human milk, fortified human milk, or special premature formula: use of serum procollagen as a marker of growth. Am J Dis Child 1987; 141: 511-515.
83. Greer FR, Chen X, McCormick A. Urinary hydroxyproline: relationship to growth, bone mineral content, and serum alkaline phosphatase level in premature infants. J Pediatr Gastroenterol Nutr 1991; 13: 176-181.
84. Ryan SW, Truscott J, Simpson M et al. Phosphate, alkaline phosphatase and bone mineralization in preterm neonates. Acta Paediatr 1993; 82: 518-521.
85. James JA, Mayne PD, Barnes IC et al. Growth velocity and plasma alkaline phosphatase activity in the preterm infant. Early Hum Devel 1985; 11: 27-32.
86. Kovar I, Mayne P, Barltrop D. Plasma alkaline phosphatase activity: a screening test for rickets in preterm neonates. Lancet 1982; i: 308-310.
87. Glass EJ, Hume R, Hendry GMA et al. Plasma alkaline phosphatase activity in rickets of prematurity. Arch Dis Child 1982; 57: 373-376.
88. Walters EG, Murphy JF, Henry P et al. Plasma alkaline phosphatase activity and its relation to rickets in pre-term infants. Ann Clin Biochem 1986; 23: 652-656.
89. Lucas A, Brooke OG, Baker BA et al. High alkaline phosphatase activity and growth in preterm neonates. Arch Dis Child 1989; 64: 902-909.
90. Lindroth M, Westgren U, Laurin S. Rickets in very low birthweight infants. Acta Paediatr Scand 1986; 75: 927-931.
91. Johansen JS, Jensen SB, Riis BJ et al. Serum bone gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapy. J Clin Endocrinol Metab 1990; 71: 122-126.
92. Spagnoli A, Branca F, Spadoni GL et al. Urinary pyridinium collagen cross-links predict growth performance in children with idiopathic short stature and with growth hormone (GH) deficiency treated with GH. Skeletal metabolism during GH treatment. J Clin Endocrinol Metab 1996; 81: 3589-3593.
93. Branca F, Robins S, Ferro-Luzzi A et al. Bone turnover in malnourished children. Lancet 1992; 340: 1493-1496.
94. Pratico G, Caltabiano L, Bottaro G et al. Serum levels of osteocalcin and type I procollagen in children with celiac disease. J Pediatr Gastroenterol Nutr 1997; 24: 170-173.
95. Jansson U, Kristiansson B, Larsson B et al. Biochemical markers of growth decrease during gluten challenge not only due to weight fall. Horm Res 1997; 48(suppl2): 75.
96. Hyams JS, Moore RE, Leichtner AM et al. Relationship of type I procollagen to corticosteroid therapy in children with inflammatory bowel disease. J Pediatr 1988; 112: 893-898.
97. Hyams JS, Moore RE, Leichtner AM et al. Longitudinal assessment of type I procollagen in children with inflammatory bowel disease subjected to surgery. J Pediatr Gastroenterol Nutr 1989; 8: 68-74.
98. Crofton PM, Ahmed SF, Wade JC et al. Effects of intensive chemotherapy on bone turnover and the growth hormone axis in children with acute lymphoblastic leukaemia. J Clin Endocrinol Metab 1998; 83: 3121-3129.
99. Crofton PM, Ahmed SF, Wade JC et al. Growth markers during third intensification in children with acute lymphoblastic leukaemia. Horm Res 1997; 48(suppl 2): 62.
100. König P, Hillman L, Cervantes C et al. Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate. J Pediatr 1993; 122: 219-226.
101. Sorva R, Turpeinen M, Juntunen-Backman K et al. Effects of inhaled budesonide on serum markers of bone metabolism in children with asthma. J Allergy Clin Immunol 1992; 90: 808-815.
102. Birkebaek NH, Esberg G, Andersen K et al. Bone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate. Arch Dis Child 1995; 73: 524-527.
103. Heuck C, Wolthers OD, Kollerup G et al. Correlation between short term lower leg growth and markers of bone and collagen turnover. Horm Res 1996; 46(suppl 2): 29.
104. Wolthers OD, Heuck C, Ternowitz T et al. The insulin-like growth factor axis and bone and collagen turnover in children with atopic dermatitis treated with topical steroids. Horm Res 1996; 46(suppl 2): 85.
105. Schwartz AM, Leonidas JC. Methotrexate osteopathy. Skeletal Radiol 1984; 11: 13-16.
106. Garnero P, Shin WJ, Gineyts E et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693-1700.
107. Bettica P, Bevilacqua M, Vago T et al. Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared. J Clin Endocrinol Metab 1997; 82: 3034-3039.
108. Allgrove J. Bisphosphonates: paediatric indications: advantages and possible side effects. In: Schönau E, Ed. Paediatric osteology: new developments in diagnostics and therapy. Amsterdam: Elsevier, 1996; 261-273.
109. Allgrove J. Bisphosphonates. Arch Dis Child 1997; 76: 73-75.
110. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine 1997; 76: 266-283.
111. Glorieux FH. Bisphosphonates: an efficient way to control bone resorption in growing children. Studies in fibrous dysplasia of bone. In: Schönau E, Ed. Paediatric osteology: new developments in diagnostics and therapy. Amsterdam: Elsevier, 1996; 275-277.